BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsCompany update

Nes-Ziona, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a 1-for-16 reverse split (the "Reverse Split") of its ordinary shares, which will become effective on October 27, 2026, on which date the Company's...

Related news

ENLVEnlivex Therapeutics2026-10-27 13:00 EST

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

ENLVEnlivex Therapeutics2026-09-22 13:00 EST

Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens

REPLReplimune Group2026-10-22 12:00 EST

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

CADLCandel Therapeutics2026-10-29 13:00 EST

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

REPLReplimune Group2026-10-01 20:01 EST

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

BMYBMYBristol-Myers Squibb Company2026-09-18 10:59 EST

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-11-02 14:00 EST

Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response

ENLVEnlivex Therapeutics2026-10-28 13:00 EST

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

ENLVEnlivex Therapeutics2026-10-28 13:00 EST

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

ENLVEnlivex Therapeutics2026-10-27 13:00 EST

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

ENLVEnlivex Therapeutics2026-10-27 13:00 EST

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

Stock data

Close
1.27 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States